The potential of TDP-43 PET ligands for a biological diagnosis of TDP-43 proteinopathies

Abstract

Candidate PET ligands targeting pathological TDP-43 aggregates are characterized by Vokali and colleagues in a series of human tissue, cell/animal model, and non-human primate experiments. Their preclinical data suggests favorable specificity and pharmacokinetic profiles of their two candidate tracers, which could translate into a disease-specific biomarker in TDP-43 proteinopathies.